Rigel Pharmaceuticals. (RIGL) NASDAQ
$1.10 (0.03) (-2.67%)
Market Cap: $197.33M
As of 04/25/24 03:59 PM EDT. Market closed.
Rigel Pharmaceuticals. (RIGL)
NASDAQ
$1.10
(0.03) (-2.67%)
Market Cap: $197.33M
As of 04/25/24 03:59 PM EDT. Market closed.
Add to Portfolio
rigel pharmaceuticals, inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare ... read more
COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
Raul Rodriguez
Full Time Employees
280
CEO Compensation (Base)
$636,540
CEO Compensation (Total)
$3.98M
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
Raul Rodriguez
Full Time Employees
280
CEO Compensation (Base)
$636,540
CEO Compensation (Total)
$3.98M
URL
Address
1180 Veterans Blvd, California, South San Francisco, 94080-1985.
PRICE CHART FOR RIGEL PHARMACEUTICALS
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$1.13
Previous Close
$1.13
Days Range
$1.11 - $1.15
52 week range
$0.71 - $1.96
Volume
2,969,722
Avg. Volume (30 days)
1,914,563
Market Cap
$197.33M
Dividend Yield
-
P/E
(7.86)
Shares Outstanding
175,404,663
Open
$1.13
Previous Close
$1.13
Days Range
$1.11 - $1.15
52 week range
$0.71 - $1.96
Volume
2,969,722
Avg. Volume (30 days)
1,914,563
Market Cap
$197.33M
Dividend Yield
-
P/E
(7.86)
Shares Outstanding
175,404,663
FINANCIAL STATEMENTS FOR RIGEL PHARMACEUTICALS
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR RIGEL PHARMACEUTICALS
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Santos David A | EVP, Chief Commercial Officer | Feb 05, 2024 | Sale | $1.14 | 8,918 | 10,167 | 349,093 | Feb 06, 2024, 08:18 PM |
| Santos David A | EVP, Chief Commercial Officer | Feb 02, 2024 | Sale | $1.13 | 5,601 | 6,329 | 358,011 | Feb 06, 2024, 08:18 PM |
| Schorno Dean L | EVP & Chief Financial Officer | Feb 05, 2024 | Sale | $1.14 | 7,027 | 8,011 | 402,891 | Feb 06, 2024, 08:18 PM |
| Schorno Dean L | EVP & Chief Financial Officer | Feb 02, 2024 | Sale | $1.13 | 5,601 | 6,327 | 409,918 | Feb 06, 2024, 08:18 PM |
| RODRIGUEZ RAUL R | CEO, President | Feb 05, 2024 | Sale | $1.14 | 30,545 | 34,821 | 2,036,629 | Feb 06, 2024, 08:18 PM |
| RODRIGUEZ RAUL R | CEO, President | Feb 02, 2024 | Sale | $1.13 | 22,349 | 25,261 | 2,067,174 | Feb 06, 2024, 08:18 PM |
| RODRIGUEZ RAUL R | CEO, President | Feb 06, 2023 | Sale | $1.75 | 20,340 | 35,595 | 1,680,713 | Feb 07, 2023, 04:30 PM |
| Santos David A | EVP, Chief Commercial Officer | Feb 02, 2023 | Sale | $1.66 | 5,388 | 8,945 | 144,612 | Feb 06, 2023, 05:41 PM |
| Schorno Dean L | EVP & Chief Financial Officer | Feb 02, 2023 | Sale | $1.66 | 5,389 | 8,946 | 196,519 | Feb 06, 2023, 05:40 PM |
| Dummer Wolfgang | EVP & CMO | Feb 02, 2023 | Sale | $1.66 | 5,389 | 8,946 | 72,459 | Feb 06, 2023, 05:40 PM |
| RODRIGUEZ RAUL R | CEO, President | Jun 09, 2022 | Buy | $0.69 | 1,000,000 | 688,400 | 1,391,776 | Jun 13, 2022, 04:36 PM |
| Schorno Dean L | EVP &Chief Financial Officer | May 22, 2019 | Buy | $2.13 | 50,000 | 106,544 | 50,000 | May 23, 2019, 08:21 PM |
| Cabatuan Nelson | Principal Accounting Officer | Oct 12, 2018 | Sale | $3.12 | 10,000 | 31,200 | 58 | Oct 16, 2018, 06:46 PM |
| Duliege Anne-Marie | EVP & Chief Medical Officer | Sep 17, 2018 | Option Exercise | $2.43 | 153,000 | 372,495 | 115,500 | Sep 19, 2018, 06:26 PM |
| Duliege Anne-Marie | EVP & Chief Medical Officer | Sep 17, 2018 | Sale | $3.50 | 153,000 | 535,500 | 0 | Sep 19, 2018, 06:26 PM |
| Mayer Eldon C. III | EVP & Chief Commercial Officer | Sep 11, 2018 | Buy | $3.23 | 50,000 | 161,340 | 215,000 | Sep 12, 2018, 12:00 AM |
| Mayer Eldon C. III | EVP & Chief Commercial Officer | Sep 10, 2018 | Buy | $3.28 | 50,000 | 164,210 | 165,000 | Sep 12, 2018, 12:00 AM |
| Duliege Anne-Marie | EVP & Chief Medical Officer | Sep 04, 2018 | Option Exercise | $2.54 | 16,500 | 41,910 | 16,500 | Sep 06, 2018, 07:02 PM |
| Duliege Anne-Marie | EVP & Chief Medical Officer | Sep 04, 2018 | Sale | $3.51 | 16,500 | 57,861 | 0 | Sep 06, 2018, 07:02 PM |
| Mayer Eldon C. III | EVP & Chief Commercial Officer | Aug 23, 2018 | Buy | $2.82 | 100,000 | 282,320 | 115,000 | Aug 27, 2018, 07:49 PM |
| RODRIGUEZ RAUL R | CEO, President | Aug 17, 2018 | Buy | $2.63 | 114,000 | 300,002 | 173,519 | Aug 21, 2018, 07:12 PM |
| Duliege Anne-Marie | EVP & Chief Medical Officer | Jul 02, 2018 | Sale | $2.79 | 5,000 | 13,932 | 0 | Jul 05, 2018, 06:59 PM |
| Duliege Anne-Marie | EVP & Chief Medical Officer | Apr 20, 2018 | Sale | $4.11 | 5,000 | 20,550 | 0 | Apr 24, 2018, 09:06 PM |
| Maynard Ryan D | EVP & CFO | Nov 03, 2017 | Option Exercise | $2.14 | 100,000 | 214,000 | 100,000 | Nov 07, 2017, 09:07 PM |
| Maynard Ryan D | EVP & CFO | Nov 03, 2017 | Sale | $3.90 | 100,000 | 390,000 | 0 | Nov 07, 2017, 09:07 PM |
| Duliege Anne-Marie | Chief Medical Officer | Jul 05, 2017 | Sale | $2.69 | 5,000 | 13,427 | 0 | Jul 07, 2017, 05:39 PM |
| Duliege Anne-Marie | Chief Medical Officer | Jan 03, 2017 | Sale | $2.41 | 5,000 | 12,027 | 0 | Jan 13, 2017, 06:02 PM |
| PAYAN DONALD G | EVP, Pres. Discovery&Research | Aug 30, 2016 | Sale | $4.00 | 5,303 | 21,214 | 53,031 | Sep 01, 2016, 06:18 PM |
| PAYAN DONALD G | EVP, Pres. Discovery&Research | Jun 10, 2015 | Option Exercise | $2.14 | 41,666 | 89,165 | 100,000 | Jun 12, 2015, 07:22 PM |
| PAYAN DONALD G | EVP, Pres. Discovery&Research | Jun 10, 2015 | Sale | $3.68 | 41,666 | 153,214 | 58,334 | Jun 12, 2015, 07:22 PM |
| PAYAN DONALD G | EVP, Pres. Discovery&Research | Apr 01, 2015 | Sale | $3.75 | 10,000 | 37,518 | 58,334 | Apr 03, 2015, 08:35 PM |
| VANCE DOLLY | EVP Corp. Affairs, G.C., Sect. | Dec 18, 2014 | Sale | $2.22 | 1,000 | 2,220 | 575 | Dec 22, 2014, 06:26 PM |
| VANCE DOLLY | EVP Corp. Affairs, G.C., Sect. | Dec 18, 2014 | Sale | $2.22 | 1,000 | 2,220 | 575 | Dec 19, 2014, 06:56 PM |
| PAYAN DONALD G | EVP, Pres. Discovery&Research | Sep 03, 2014 | Sale | $2.56 | 20,000 | 51,200 | 68,334 | Sep 05, 2014, 06:07 PM |
| PAYAN DONALD G | EVP, Pres. Discovery&Research | Feb 24, 2014 | Sale | $3.71 | 20,000 | 74,238 | 88,334 | Feb 26, 2014, 07:21 PM |
| BVF PARTNERS L P/IL | 10% Owner | Nov 19, 2013 | Sale | $2.64 | 484,622 | 1,280,274 | 1,123,848 | Nov 20, 2013, 02:13 PM |
| BVF PARTNERS L P/IL | 10% Owner | Jun 07, 2013 | Buy | $3.47 | 32,700 | 113,394 | 1,455,414 | Jun 11, 2013, 05:55 PM |
| Maynard Ryan D | EVP & CFO | Sep 12, 2012 | Option Exercise | $6.49 | 23,302 | 151,230 | 23,302 | Sep 14, 2012, 07:57 PM |
| Maynard Ryan D | EVP & CFO | Sep 12, 2012 | Sale | $10.67 | 23,302 | 248,560 | 0 | Sep 14, 2012, 07:57 PM |
| VANCE DOLLY | EVP Corp. Affairs, G.C., Sect. | Sep 13, 2012 | Sale | $10.43 | 4,151 | 43,284 | 1,103 | Sep 14, 2012, 06:45 PM |
| Maynard Ryan D | EVP & CFO | Sep 07, 2012 | Option Exercise | $6.49 | 23,302 | 151,230 | 23,302 | Sep 14, 2012, 06:19 PM |
| Maynard Ryan D | EVP & CFO | Sep 07, 2012 | Sale | $10.67 | 23,302 | 248,560 | 0 | Sep 14, 2012, 06:19 PM |
| Maynard Ryan D | EVP & CFO | Sep 10, 2012 | Option Exercise | $6.49 | 17,586 | 114,133 | 17,586 | Sep 11, 2012, 06:07 PM |
| Maynard Ryan D | EVP & CFO | Sep 07, 2012 | Option Exercise | $6.49 | 34,112 | 221,387 | 34,112 | Sep 11, 2012, 06:07 PM |
| Maynard Ryan D | EVP & CFO | Sep 10, 2012 | Sale | $10.52 | 17,586 | 184,927 | 0 | Sep 11, 2012, 06:07 PM |
| Maynard Ryan D | EVP & CFO | Sep 07, 2012 | Sale | $10.55 | 34,112 | 359,960 | 0 | Sep 11, 2012, 06:07 PM |
| Maynard Ryan D | EVP & CFO | Aug 07, 2012 | Option Exercise | $6.49 | 1,700 | 11,033 | 1,700 | Aug 09, 2012, 05:39 PM |
| Maynard Ryan D | EVP & CFO | Aug 07, 2012 | Sale | $10.61 | 1,700 | 18,041 | 1,000 | Aug 09, 2012, 05:39 PM |
| PAYAN DONALD G | EVP, Pres. Discovery&Research | Jun 19, 2012 | Sale | $8.70 | 10,000 | 87,008 | 118,234 | Jun 20, 2012, 05:45 PM |
| Flynn James E | 10% Owner | May 26, 2011 | Buy | $8.00 | 301,424 | 2,411,392 | 3,204,167 | Jun 07, 2011, 05:27 PM |
| Flynn James E | 10% Owner | May 26, 2011 | Buy | $8.00 | 229,252 | 1,834,016 | 2,279,997 | Jun 07, 2011, 05:27 PM |
| Flynn James E | 10% Owner | May 26, 2011 | Buy | $8.00 | 72,800 | 582,400 | 762,700 | Jun 07, 2011, 05:27 PM |
| Flynn James E | 10% Owner | May 26, 2011 | Buy | $8.00 | 46,524 | 372,192 | 470,425 | Jun 07, 2011, 05:27 PM |
| Flynn James E | 10% Owner | Nov 03, 2010 | Sale | $7.55 | 516 | 3,896 | 423,901 | Nov 05, 2010, 05:39 PM |
| Flynn James E | 10% Owner | Nov 03, 2010 | Sale | $7.55 | 3,690 | 27,860 | 2,902,743 | Nov 05, 2010, 05:39 PM |
| Flynn James E | 10% Owner | Nov 03, 2010 | Sale | $7.55 | 2,605 | 19,668 | 2,050,745 | Nov 05, 2010, 05:39 PM |
| Flynn James E | 10% Owner | Nov 03, 2010 | Sale | $7.55 | 900 | 6,795 | 689,900 | Nov 05, 2010, 05:39 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Santos David A | EVP, Chief Commercial Officer | 02/05/2024 | 10,167 |
| Santos David A | EVP, Chief Commercial Officer | 02/02/2024 | 6,329 |
| Schorno Dean L | EVP & Chief Financial Officer | 02/05/2024 | 8,011 |
| Schorno Dean L | EVP & Chief Financial Officer | 02/02/2024 | 6,327 |
| RODRIGUEZ RAUL R | CEO, President | 02/05/2024 | 34,821 |
| RODRIGUEZ RAUL R | CEO, President | 02/02/2024 | 25,261 |
| RODRIGUEZ RAUL R | CEO, President | 02/06/2023 | 35,595 |
| Santos David A | EVP, Chief Commercial Officer | 02/02/2023 | 8,945 |
| Schorno Dean L | EVP & Chief Financial Officer | 02/02/2023 | 8,946 |
| Dummer Wolfgang | EVP & CMO | 02/02/2023 | 8,946 |
| RODRIGUEZ RAUL R | CEO, President | 06/09/2022 | 688,400 |
| Schorno Dean L | EVP &Chief Financial Officer | 05/22/2019 | 106,544 |
| Cabatuan Nelson | Principal Accounting Officer | 10/12/2018 | 31,200 |
| Duliege Anne-Marie | EVP & Chief Medical Officer | 09/17/2018 | 372,495 |
| Duliege Anne-Marie | EVP & Chief Medical Officer | 09/17/2018 | 535,500 |
| Mayer Eldon C. III | EVP & Chief Commercial Officer | 09/11/2018 | 161,340 |
| Mayer Eldon C. III | EVP & Chief Commercial Officer | 09/10/2018 | 164,210 |
| Duliege Anne-Marie | EVP & Chief Medical Officer | 09/04/2018 | 41,910 |
| Duliege Anne-Marie | EVP & Chief Medical Officer | 09/04/2018 | 57,861 |
| Mayer Eldon C. III | EVP & Chief Commercial Officer | 08/23/2018 | 282,320 |
| RODRIGUEZ RAUL R | CEO, President | 08/17/2018 | 300,002 |
| Duliege Anne-Marie | EVP & Chief Medical Officer | 07/02/2018 | 13,932 |
| Duliege Anne-Marie | EVP & Chief Medical Officer | 04/20/2018 | 20,550 |
| Maynard Ryan D | EVP & CFO | 11/03/2017 | 214,000 |
| Maynard Ryan D | EVP & CFO | 11/03/2017 | 390,000 |
| Duliege Anne-Marie | Chief Medical Officer | 07/05/2017 | 13,427 |
| Duliege Anne-Marie | Chief Medical Officer | 01/03/2017 | 12,027 |
| PAYAN DONALD G | EVP, Pres. Discovery&Research | 08/30/2016 | 21,214 |
| PAYAN DONALD G | EVP, Pres. Discovery&Research | 06/10/2015 | 89,165 |
| PAYAN DONALD G | EVP, Pres. Discovery&Research | 06/10/2015 | 153,214 |
| PAYAN DONALD G | EVP, Pres. Discovery&Research | 04/01/2015 | 37,518 |
| VANCE DOLLY | EVP Corp. Affairs, G.C., Sect. | 12/18/2014 | 2,220 |
| VANCE DOLLY | EVP Corp. Affairs, G.C., Sect. | 12/18/2014 | 2,220 |
| PAYAN DONALD G | EVP, Pres. Discovery&Research | 09/03/2014 | 51,200 |
| PAYAN DONALD G | EVP, Pres. Discovery&Research | 02/24/2014 | 74,238 |
| BVF PARTNERS L P/IL | 10% Owner | 11/19/2013 | 1,280,274 |
| BVF PARTNERS L P/IL | 10% Owner | 06/07/2013 | 113,394 |
| Maynard Ryan D | EVP & CFO | 09/12/2012 | 151,230 |
| Maynard Ryan D | EVP & CFO | 09/12/2012 | 248,560 |
| VANCE DOLLY | EVP Corp. Affairs, G.C., Sect. | 09/13/2012 | 43,284 |
| Maynard Ryan D | EVP & CFO | 09/07/2012 | 151,230 |
| Maynard Ryan D | EVP & CFO | 09/07/2012 | 248,560 |
| Maynard Ryan D | EVP & CFO | 09/10/2012 | 114,133 |
| Maynard Ryan D | EVP & CFO | 09/07/2012 | 221,387 |
| Maynard Ryan D | EVP & CFO | 09/10/2012 | 184,927 |
| Maynard Ryan D | EVP & CFO | 09/07/2012 | 359,960 |
| Maynard Ryan D | EVP & CFO | 08/07/2012 | 11,033 |
| Maynard Ryan D | EVP & CFO | 08/07/2012 | 18,041 |
| PAYAN DONALD G | EVP, Pres. Discovery&Research | 06/19/2012 | 87,008 |
| Flynn James E | 10% Owner | 05/26/2011 | 2,411,392 |
| Flynn James E | 10% Owner | 05/26/2011 | 1,834,016 |
| Flynn James E | 10% Owner | 05/26/2011 | 582,400 |
| Flynn James E | 10% Owner | 05/26/2011 | 372,192 |
| Flynn James E | 10% Owner | 11/03/2010 | 3,896 |
| Flynn James E | 10% Owner | 11/03/2010 | 27,860 |
| Flynn James E | 10% Owner | 11/03/2010 | 19,668 |
| Flynn James E | 10% Owner | 11/03/2010 | 6,795 |
Load More Insider Transactions
FUNDS WITH A POSITION IN RIGEL PHARMACEUTICALS
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| BLACKROCK INC. | 15,198,077 | 0.00056% | 5.44% | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 3,692,699 | 0.00056% | 4.1% | Other |
| RENAISSANCE TECHNOLOGIES LLC | 1,318,226 | 0.00296% | 16.47% | Other |
| UBS OCONNOR LLC | 899,335 | 0.09% | -21.92% | Value |
CHANGE IN SHARES OUTSTANDING FOR RIGEL PHARMACEUTICALS
STOCK BUYBACKS FOR RIGEL PHARMACEUTICALS
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
0.01%
1Q
06/30/2023
0.36%
2Q
03/31/2023
0.47%
3Q
12/31/2022
0.88%
4Q
09/30/2022
0.89%
5Q
06/30/2022
1.30%
6Q
03/31/2022
1.52%
7Q
12/31/2021
14.26%
8Q
09/30/2021
2.04%
9Q
06/30/2021
2.46%
10Q
03/31/2021
-0.96%
11Q
12/31/2020
3.16%
12Q
09/30/2020
3.22%
13Q
06/30/2020
3.44%
14Q
03/31/2020
3.45%
15Q
12/31/2019
4.03%
16Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR RIGEL PHARMACEUTICALS
LOADING...